Hologic, Inc. (HOLX)
NASDAQ: HOLX · Real-Time Price · USD
60.86
-0.83 (-1.35%)
At close: Apr 4, 2025, 4:00 PM
61.98
+1.12 (1.84%)
After-hours: Apr 4, 2025, 7:34 PM EDT
Hologic Revenue
Hologic had revenue of $1.02B in the quarter ending December 28, 2024, with 0.86% growth. This brings the company's revenue in the last twelve months to $4.04B, up 1.76% year-over-year. In the fiscal year ending September 28, 2024, Hologic had annual revenue of $4.03B, down -0.00%.
Revenue (ttm)
$4.04B
Revenue Growth
+1.76%
P/S Ratio
3.52
Revenue / Employee
$577,825
Employees
6,990
Market Cap
13.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 28, 2024 | 4.03B | -100.00K | -0.00% |
Sep 30, 2023 | 4.03B | -832.40M | -17.12% |
Sep 24, 2022 | 4.86B | -769.50M | -13.66% |
Sep 25, 2021 | 5.63B | 1.86B | 49.14% |
Sep 26, 2020 | 3.78B | 409.10M | 12.15% |
Sep 28, 2019 | Pro | Pro | Pro |
Sep 29, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 24, 2016 | Pro | Pro | Pro |
Sep 26, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
HOLX News
- 2 days ago - Wayde McMillan Elected to Hologic Board of Directors - Business Wire
- 3 days ago - Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025 - Business Wire
- 5 weeks ago - Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference - Business Wire
- 6 weeks ago - Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software - Business Wire
- 6 weeks ago - Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay - Business Wire
- 2 months ago - Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Hologic cuts annual revenue forecast on weak demand for breast health products - Reuters
- 2 months ago - Hologic Announces Financial Results for First Quarter of Fiscal 2025 - Business Wire